Plus Therapeutics, Inc. (PSTV)
NASDAQ: PSTV · Real-Time Price · USD
0.5298
-0.0667 (-11.18%)
At close: Jul 25, 2025, 4:00 PM
0.5252
-0.0046 (-0.87%)
After-hours: Jul 25, 2025, 7:59 PM EDT
Plus Therapeutics Employees
Plus Therapeutics had 21 employees as of December 31, 2024. The number of employees increased by 1 or 5.00% compared to the previous year.
Employees
21
Change (1Y)
1
Growth (1Y)
5.00%
Revenue / Employee
$247,905
Profits / Employee
-$1,291,333
Market Cap
32.05M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PSTV News
- 2 days ago - Plus Therapeutics Announces $1.6 Million Advance Payment from CPRIT - GlobeNewsWire
- 10 days ago - Plus Therapeutics Presents ReSPECT-LM Clinical Trial Results for REYOBIQ™ in Patients with Leptomeningeal Metastases - GlobeNewsWire
- 15 days ago - Plus Therapeutics Announces Two CNSide Presentations at the Upcoming SNO/ASCO CNS Metastases Conference - GlobeNewsWire
- 17 days ago - Plus Therapeutics Announces Initial Patients Successfully Treated in ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases - GlobeNewsWire
- 25 days ago - Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ™ in Leptomeningeal Metastases - GlobeNewsWire
- 4 weeks ago - Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary - GlobeNewsWire
- 4 weeks ago - Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, June 26, 2025 at 9:00 A.M. ET - GlobeNewsWire
- 4 weeks ago - Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer - GlobeNewsWire